Overview: EBER In Situ Hybridization TestIntroduction: The EBER In Situ Hybridization Test detects Epstein-Barr virus (EBV) early RNA to diagnose lymphomas or EBV-related cancers, causing swelling or fever. Aligned with 2023 WHO guidelines, it uses in-situ hybridization for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected EBV-associated malignancies.
Other Names: EBER-ISH Assay, EBV-Related Cancer Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: EBER testing began in the 1990s with EBV research. In-situ hybridization methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects EBV RNA to diagnose lymphomas or EBV-related cancers, guides treatment, and evaluates patients with swelling or fever.
Test Parameters: 1. Epstein-Barr Virus Early RNA
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of swelling, fever, or lymphoma symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document swelling, fever, night sweats, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses in-situ hybridization to detect EBER in tissue. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for EBV-related cancer diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce hybridization accuracy.
Clinical Significance: Positive EBER staining confirms EBV-related lymphomas or cancers (e.g., nasopharyngeal carcinoma), guiding chemotherapy or immunotherapy. Negative staining may require further testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: LMP1 IHC, CD30 IHC, or PET-CT to confirm EBV-related cancer diagnosis.
Test Limitations: Not specific to one EBV-related cancer; clinical correlation is needed. Other viral infections may complicate interpretation.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
